A Double-Blind, Placebo Controlled, Randomized, Two Centre Phase IIA Pharmacodynamic Cross-Over Study to Assess the Effect of AZD3355, 65 mg Bid, on Transient Lower Esophageal Sphincter Relaxations (TLESRs) in GERD Patients With an Incomplete Response to PPI Treatment.

Trial Profile

A Double-Blind, Placebo Controlled, Randomized, Two Centre Phase IIA Pharmacodynamic Cross-Over Study to Assess the Effect of AZD3355, 65 mg Bid, on Transient Lower Esophageal Sphincter Relaxations (TLESRs) in GERD Patients With an Incomplete Response to PPI Treatment.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jul 2013

At a glance

  • Drugs Lesogaberan (Primary)
  • Indications Gastro-oesophageal reflux
  • Focus Pharmacodynamics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 05 May 2010 Results published in Gastroenterology.
    • 17 Nov 2009 Results to be presented at the GASTRO 2009 joint meeting (UEGW/WCOG).
    • 12 Jun 2009 Trial phase changed from I/II to II as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top